Terms ending in 2039
Every in-force patent on Amgen Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US D1,010,107 | Handheld Drug Delivery Device In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 12,251,743 | Method of Preventing Lamellar Silica Formation in Glass Container In force · Medium confidence | Amgen Inc. | In force | Medium confidence | |
| US D1,010,811 | Handheld Drug Delivery Device In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 11,541,103 | Interleukin-21 Mutein/ Anti-PD-1 Antibody Conjugates In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 10,738,110 | PAC1 Antibodies and Uses Thereof In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 11,248,043 | Methods for Treating a Headache Condition Using Anti-Human PAC1 Antibodies or Antigen-Binding Fragments Thereof In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 11,891,435 | Polynucleotides Encoding Monoclonal Antibodies Binding to Human Pituitary Adenylate Cyclase-Activating Polypeptide Type I Receptor (PAC1) and Methods of Making Thereof In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 12,790,388 | Anti-Human PAC1 Antibodies or Antigen-Binding Fragments Thereof and Methods of Use Thereof for Inhibiting Vasodilation and Ameliorating a Headache Condition In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 11,541,183 | Device Activation Impact/Shock Reduction In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 12,516,111 | Direct Selection of Cells Expressing High Levels of Heteromeric Proteins Using Glutamine Synthetase Intragenic Complementation Vectors In force · High confidence | Amgen Inc. | In force | High confidence | |
| 75 more term ends in 2039 · Pro | |||||
10 of 85 patents shown. Soonest term end first, then patent number.
Pro members see all 85.
80 of these are in force and held by Amgen Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.